Involvement of ERK signaling in halofuginone-driven inhibition of fibroblast ability to contract collagen lattices

European Journal of Pharmacology

Volumn 573, Issue 1-3, 2007, Pages 65-69

  Tacheau, Charlotte ^a   Michel, Laurence ^a   Farge, Dominique ^a   Mauviel, Alain ^a   Verrecchia, Franck ^a  

^a INSERM   (France)

Author keywords

Extracellular matrix contraction; Fibrosis; Halofuginone; Tissue repair

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ALKALOID; COLLAGEN; HALOFUGINONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE 1;

ARTICLE; CELL CYCLE; CONTROLLED STUDY; DICHROA FEBRIFUGA; DRUG MECHANISM; FIBROBLAST; FIBROSIS; HUMAN; HUMAN CELL; PLANT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WOUND HEALING;

BLOTTING, WESTERN; BUTADIENES; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR MATRIX; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; FLAVONOIDS; HUMANS; IMIDAZOLES; MAP KINASE SIGNALING SYSTEM; NITRILES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PIPERIDINES; PROTEIN SYNTHESIS INHIBITORS; PYRIDINES; QUINAZOLINONES; TIME FACTORS;

EID: 34648837926     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.07.030     Document Type: Article

References (22)

1. Desmouliere A., Chaponnier C., and Gabbiani G. Tissue repair, contraction, and the myofibroblast. Wound Repair Regen. 13 (2005) 7-12
2. Eckes B., Zigrino P., Kessler D., Holtkotter O., Shephard P., Mauch C., and Krieg T. Fibroblast-matrix interactions in wound healing and fibrosis. Matrix Biol. 19 (2000) 325-332
3. Flanders K.C. Smad3 as a mediator of the fibrotic response. Int. J. Exp. Pathol. 85 (2004) 47-64
4. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J. Pathol. 200 (2003) 500-503
5. Gnainsky Y., Spira G., Paizi M., Bruck R., Nagler A., Genina O., Taub R., Halevy O., and Pines M. Involvement of the tyrosine phosphatase early gene of liver regeneration (PRL-1) in cell cycle and in liver regeneration and fibrosis effect of halofuginone. Cell Tissue Res. 324 (2006) 385-394
6. Granot I., Halevy O., Hurwitz S., and Pines M. Halofuginone: an inhibitor of collagen type I synthesis. Biochim. Biophys. Acta 1156 (1993) 107-112
7. Javelaud D., Laboureau J., Gabison E., Verrecchia F., and Mauviel A. Disruption of basal JNK activity differentially affects key fibroblast functions important for wound healing. J. Biol. Chem. 278 (2003) 24624-24628
8. Kamakura S., Moriguchi T., and Nishida E. Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J. Biol. Chem. 274 (1999) 26563-26571
9. Lee D.J., Rosenfeldt H., and Grinnell F. Activation of ERK and p38 MAP kinases in human fibroblasts during collagen matrix contraction. Exp. Cell Res. 257 (2000) 190-197
10. McGaha T.L., Kodera T., Spiera H., Stan A.C., Pines M., and Bona C.A. Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism. Arthritis Rheum. 46 (2002) 2748-2761
11. Pines M., and Nagler A. Halofuginone: a novel antifibrotic therapy. Gen. Pharmacol. 30 (1998) 445-450
12. Pines M., Snyder D., Yarkoni S., and Nagler A. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol. Blood Marrow Transplant. 9 (2003) 417-425
13. Poulalhon N., Farge D., Roos N., Tacheau C., Neuzillet C., Michel L., Mauviel A., and Verrecchia F. Modulation of collagen and MMP-1 gene expression in fibroblasts by the immunosuppressive drug rapamycin. A direct role as an antifibrotic agent?. J. Biol. Chem. 281 (2006) 33045-33052
14. Roos N., Poulalhon N., Farge D., Madeleine I., Mauviel A., and Verrecchia F. In vitro evidence for a direct anti-fibrotic role of the immunosupressive drug mycophenolate mofetil. J. Pharmacol. Exp. Ther. 321 (2007) 583-589
15. Rosenfeldt H., and Grinnell F. Fibroblast quiescence and the disruption of ERK signaling in mechanically unloaded collagen matrices. J. Biol. Chem. 275 (2000) 3088-3092
16. Rosenfeldt H., Lee D.J., and Grinnell F. Increased c-fos mRNA expression by human fibroblasts contracting stressed collagen matrices. Mol. Cell. Biol. 18 (1998) 2659-2667
17. Singer A.J., and Clark R.A. Cutaneous wound healing. N. Engl. J. Med. 341 (1999) 738-746
18. Trojanowska M., LeRoy E.C., Eckes B., and Krieg T. Pathogenesis of fibrosis: type 1 collagen and the skin. J. Mol. Med. 76 (1998) 266-274
19. Uitto J., and Kouba D. Cytokine modulation of extracellular matrix gene expression: relevance to fibrotic skin diseases. J. Dermatol. Sci. 24 Suppl 1 (2000) S60-S69
20. Verrecchia F., and Mauviel A. Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J. Invest. Dermatol. 118 (2002) 211-215
21. Verrecchia F., and Mauviel A. TGF-beta and TNF-alpha: antagonistic cytokines controlling type I collagen gene expression. Cell. Signal. 16 (2004) 873-880
22. Verrecchia F., Mauviel A., and Farge D. Transforming growth factor-β signaling through the Smad proteins: role in systemic sclerosis. Autoimmun. Rev. 5 (2006) 563-569